SummaryRMgm-5370
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption, Introduction of a transgene, Introduction of a transgene |
Reference (PubMed-PMID number) | Not published (yet) |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. yoelii |
Parent strain/line | P. y. yoelii 17XNL |
Name parent line/clone | RMgm-689 |
Other information parent line | A reference “wild type” Py17XNL parasite line 1971cl1 (RMgm-689; PyGFP-luccon). This line contains the fusion gene gfp-luciferase gene under control of the constitutive eef1α promoter integrated into the silent p230p gene locus (PY17X_0306600) and does not contain a drug-selectable marker. |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Kolli SK, Couper K, Janse CJ |
Name Group/Department | Leiden malaria Research Group, Parasitology Department |
Name Institute | Leiden University Medical Center (LUMC) |
City | Leiden |
Country | The Netherlands |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-5370 |
Principal name | 2936cl2 |
Alternative name | ΔPyFabBF-OVA::Hep17(Hep17) |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Normal blood stage development/multiplication. Expression of OVA in asexual blood stages was shown by Western and immunofluorescence analyses.OVA::HEP17 expression at the parasitophorous vacuole membrane of blood stages. |
Gametocyte/Gamete | Not tested |
Fertilization and ookinete | Not tested |
Oocyst | Not tested |
Sporozoite | Not tested |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PY17X_1126500 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0626300 | ||||||||||||||||||||||||
Gene product | 3-oxoacyl-acyl-carrier protein synthase I/II | ||||||||||||||||||||||||
Gene product: Alternative name | FabB/F | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | To generate transgenic P. yoelii mutant expressing ovalbumin (OVA) fused to Hep17/EXP1 of P. yoelii (PY17X_0928700) under the control of P. yoelii hep17 promoter, we generated DNA construct pL2244. First (step1), the promoter of hep17 (1.37 kb upstream of the start codon) and the signal peptide (SP) sequence of hep17 (bp 1-81) were PCR-amplified from wild-type P. yoelii genomic DNA and cloned into AflII/KpnI restriction sites of plasmid pL1980 that has sequences targeting the 3’ and 5’ regions of the fabb/f gene of P. yoelii (PY17X_1126500). Second (step 2), the remainder of the hep17 open reading frame (ORF) after the SP (bp 82-785), along with ∼800-bp of the 3′-UTR, was PCR-amplified and then cloned at MunI/KpnI restriction sites of the plasmid made in step 1. Third, the ORF of OVA, which was PCR-amplified from pL1884 was cloned into MunI/ BglI digested plasmid made in step 2. Finally, the hdhfr selectable marker (SM) cassette was amplified from pL0005 (MRA-774, deposited to the BEI Resources Repository) and cloned into KpnI-digested plasmid made in step 3, resulting in the final construct pL2244. In this construct the hdhfr SM is under control of the eef1a promote and the 3’UTR of Pbdhfr/ts. This construct was linearized using EcoRI/HindIII sites before transfection Transfection (exp. 2936), selection and cloning of transformed parasites was performed using standard genetic modification technologies using 1971cl1 as the parent P. yoelii XNL parasite line | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
![]() Primer information: Primers used for amplification of the target sequences
![]()
| |||||||||||||||||||||||||
top of page |
top of page | |||||||||||||||||||
Type and details of transgene | |||||||||||||||||||
Is the transgene Plasmodium derived | Transgene: not Plasmodium | ||||||||||||||||||
Transgene name | Ovalbumin (OVA ) fused to HEP17/EXP1 | ||||||||||||||||||
top of page | |||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||
Inducable system used | No | ||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||
Type of plasmid/construct | (Linear) plasmid double cross-over | ||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||
Additional remarks genetic modification | To generate transgenic P. yoelii mutant expressing ovalbumin (OVA) fused to Hep17/EXP1 of P. yoelii (PY17X_0928700) under the control of P. yoelii hep17 promoter, we generated DNA construct pL2244. First (step1), the promoter of hep17 (1.37 kb upstream of the start codon) and the signal peptide (SP) sequence of hep17 (bp 1-81) were PCR-amplified from wild-type P. yoelii genomic DNA and cloned into AflII/KpnI restriction sites of plasmid pL1980 that has sequences targeting the 3’ and 5’ regions of the fabb/f gene of P. yoelii (PY17X_1126500). Second (step 2), the remainder of the hep17 open reading frame (ORF) after the SP (bp 82-785), along with ∼800-bp of the 3′-UTR, was PCR-amplified and then cloned at MunI/KpnI restriction sites of the plasmid made in step 1. Third, the ORF of OVA, which was PCR-amplified from pL1884 was cloned into MunI/ BglI digested plasmid made in step 2. Finally, the hdhfr selectable marker (SM) cassette was amplified from pL0005 (MRA-774, deposited to the BEI Resources Repository) and cloned into KpnI-digested plasmid made in step 3, resulting in the final construct pL2244. In this construct the hdhfr SM is under control of the eef1a promote and the 3’UTR of Pbdhfr/ts. This construct was linearized using EcoRI/HindIII sites before transfection Transfection (exp. 2936), selection and cloning of transformed parasites was performed using standard genetic modification technologies using 1971cl1 as the parent P. yoelii XNL parasite line. | ||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||
top of page | |||||||||||||||||||
Other details transgene | |||||||||||||||||||
top of page | |||||||||||||||||||
Promoter | |||||||||||||||||||
Gene Model of Parasite | PY17X_0928700 | ||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1121600 | ||||||||||||||||||
Gene product | exported protein 1 | ||||||||||||||||||
Gene product: Alternative name | EXP1; Hep17 | ||||||||||||||||||
| |||||||||||||||||||
top of page | |||||||||||||||||||
3'-UTR | |||||||||||||||||||
Gene Model of Parasite | PY17X_0928700 | ||||||||||||||||||
Gene product | exported protein 1 | ||||||||||||||||||
Gene product: Alternative name | EXP1; Hep17 | ||||||||||||||||||
| |||||||||||||||||||
Insertion/Replacement locus | |||||||||||||||||||
Replacement / Insertion | Replacement locus | ||||||||||||||||||
Gene Model of Parasite | PY17X_1126500 | ||||||||||||||||||
Gene product | 3-oxoacyl-acyl-carrier protein synthase I/II | ||||||||||||||||||
Gene product: Alternative name | FabB/F | ||||||||||||||||||
| |||||||||||||||||||
top of page |
top of page | |||||||||||||||||||
Type and details of transgene | |||||||||||||||||||
Is the transgene Plasmodium derived | Transgene: not Plasmodium | ||||||||||||||||||
Transgene name | GFP-Luciferase | ||||||||||||||||||
top of page | |||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||
Inducable system used | No | ||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||
Type of plasmid/construct | (Linear) plasmid double cross-over | ||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr/yfcu | ||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||
Selection (positive) procedure | No | ||||||||||||||||||
Selection (negative) procedure | 5-fluorocytosine (5-FC) | ||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||
Additional remarks selection procedure | This reporter mutant expressing GFP-Luciferase does not contain a drug-selectable marker. The mutant has been generated in the reference line GIMOPy17x (RMgm-688). The GIMO mother line is used for introduction of transgenes into the modified 230p locus through transfection with constructs that target the 230p locus. These constructs insert into the 230p locus (‘gene insertion’), thereby removing the hdhfr::yfcu selectable marker (‘marker out’) from the genome of the mother lines. Transgenic parasites that are marker-free are subsequently selected by applying negative drug selection using 5-FC. This selection procedure is performed in vivo in mice. | ||||||||||||||||||
top of page | |||||||||||||||||||
Other details transgene | |||||||||||||||||||
top of page | |||||||||||||||||||
Promoter | |||||||||||||||||||
Gene Model of Parasite | PBANKA_1133300 | ||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1357100 | ||||||||||||||||||
Gene product | elongation factor 1-alpha | ||||||||||||||||||
Gene product: Alternative name | eef1a | ||||||||||||||||||
| |||||||||||||||||||
top of page | |||||||||||||||||||
3'-UTR | |||||||||||||||||||
Gene Model of Parasite | PBANKA_0719300 | ||||||||||||||||||
Gene product | bifunctional dihydrofolate reductase-thymidylate synthase, putative | ||||||||||||||||||
Gene product: Alternative name | dhfr/ts | ||||||||||||||||||
| |||||||||||||||||||
Insertion/Replacement locus | |||||||||||||||||||
Replacement / Insertion | Replacement locus | ||||||||||||||||||
Gene Model of Parasite | PY17X_0306600 | ||||||||||||||||||
Gene product | 6-cysteine protein | ||||||||||||||||||
Gene product: Alternative name | P230p; 230p | ||||||||||||||||||
| |||||||||||||||||||
top of page |